Product Overview
ACE‑031 (also known as Myostatin inhibitory peptide 7; research code Ramatercept) is a recombinant, soluble Activin Receptor Type IIB (ActRIIB)–IgG1‑Fc fusion protein that acts as a potent myostatin inhibitor. It neutralizes myostatin and related ligands that negatively regulate skeletal muscle mass, thereby promoting muscle growth. It has been investigated in clinical research for conditions such as Duchenne muscular dystrophy (DMD) and in healthy volunteer single‑ascending‑dose studiesReported Research Findings
In a randomized, placebo‑controlled trial in ambulatory boys with DMD, treatment with ACE‑031 led to statistically significant changes in serum biomarkers associated with muscle, bone, and fat metabolism, supporting its mechanism as a myostatin pathway inhibitor.
A single ascending‑dose study in healthy volunteers evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics, consistent with its profile as an ActRIIB decoy receptor1.
Handling and Storage
Store lyophilized powder at −20°C (stable for up to 3 years); short‑term at 4°C (up to 2 years).
After reconstitution: store at −80°C (up to 6 months) or −20°C (up to 1 month).
Avoid repeated freeze–thaw cycles;appropriate sterile techniques for handling1.
Safety and Compliance
This product is for research use only and is not intended for diagnostic or therapeutic use in humans or animals.
Reseas should review local regulations and institutional biosafety requirements to procur and use.
Note: This content is for informational purposd doe constitute medical advice or treatment recommendations
China
